Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

3.8%

1 terminated/withdrawn out of 26 trials

Success Rate

93.3%

+6.8% vs industry average

Late-Stage Pipeline

23%

6 trials in Phase 3/4

Results Transparency

0 of 14 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A

6(42.9%)

Phase 3

5(35.7%)

Phase 2

2(14.3%)

Phase 4

1(7.1%)

14Total

N/A(6)

Phase 3(5)

Phase 2(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (26)

Showing 20 of 26 trials

NCT07671287Phase 3Not Yet Recruiting

GMMG-HD11/DSMM XXI/64007957MMY3010

Role: lead

NCT05804032Phase 3Completed

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Role: lead

NCT03617731Phase 3Active Not Recruiting

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

Role: lead

NCT06216158Phase 3Recruiting

Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

Role: lead

NCT05695508Phase 2Recruiting

GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

Role: lead

NCT05358314Completed

Investigating Neuronal and Peripheral Markers of Brain Heart Interaction in Healthy Participants Under Stress

Role: lead

NCT05313347Completed

Neural Correlates of Sensory Specific Satiety